-+ 0.00%
-+ 0.00%
-+ 0.00%

Cantor Fitzgerald Maintains Overweight on AbbVie, Raises Price Target to $290

Benzinga·10/08/2026 10:38:02
Diffusion vocale
Cantor Fitzgerald analyst Carter Gould maintains AbbVie (NYSE:ABBV) with a Overweight and raises the price target from $285 to $290.